Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 13/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 3/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.33 |
| ▸ | SGK1 | O00141 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ULK1 | O75385 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | GRK2 | P25098 | 1/20 | 0.33 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.33 |
| ▸ | GRK3 | P35626 | 1/20 | 0.33 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CDK7 | P50613 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553157 | 0.83 | DPP4 (0.36) | MAPK1LMNADPP4DPP8 | |
| SCHEMBL2595112 | 0.81 | MAPK8 (0.40) | MAPK1 | |
| SCHEMBL17598745 | 0.75 | GSK3B (0.39) | DPP4DPP9GSK3B | |
| SCHEMBL4617296 | 0.74 | LMNA (0.39) | LMNADPP4 | |
| SCHEMBL26662843 | 0.72 | AGBL2 (0.33) | MAPK1ABL1 | |
| SCHEMBL4963295 | 0.70 | CYP2D6 (0.35) | MAPK1SGK1ROCK2ULK1CDK2 | |
| SCHEMBL17846217 | 0.70 | MAPK1 (0.65) | MAPK1 | |
| SCHEMBL17598976 | 0.68 | ADORA3 (0.38) | — | |
| SCHEMBL23201139 | 0.67 | GABRP (0.39) | LMNADPP4DPP9DPP8 | |
| SCHEMBL553661 | 0.66 | KLKB1 (0.44) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207695-A1 | Thrombin Inhibiting 2-Oxo-1,2,5,6-Tetrahydropyridine Derivatives | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| CN-101243069-A | Thrombin inhibiting 2-oxo-1,2,5,6-tetrahydropyridine derivatives | ASTRAZENECA AB (SE) | 2008-08-13 | — | — | CN | disclosed |
| EP-1893601-A1 | THROMBIN INHIBITING 2-OXO-1, 2, 5, 6-TETRAHYDROPYRIDINE DERIVATIVES | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006135323-A1 | THROMBIN INHIBITING 2-OXO-1, 2, 5, 6-TETRAHYDROPYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207695-A1 | Thrombin Inhibiting 2-Oxo-1,2,5,6-Tetrahydropyridine Derivatives | F2R, F2, SERPINE1 | MAPK1 1599/4885LMNA 2604/4885DPP4 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.